Groupama Asset Management cut its stake in Amgen by nearly 15% in Q4, selling off over 3,000 shares. At quarter’s end, their ...

In a report released on April 3, Gregory Renza from RBC Capital maintained a Buy rating on Agios Pharma (AGIO – Research Report), with a price ...

Biosimilar challenges include complex manufacturing processes and regulatory obstacles, offset by less regulated market ...

With a label expansion for Uplizna pushing the drug into an untouched rare disease market, Amgen is getting its money’s worth ...

The global US Autoinjectors Market is projected to expand to a value of US$1.45 billion in 2030 from US$0.65 billion in 2024, ...

Shares of medicine manufacturer Amgen Inc (AMGN) are in the spotlight on Friday after it announced that the U.S. Food and ...

Amgen (NASDAQ: NASDAQ:AMGN) announced that the U.S. Food and Drug Administration (FDA) has granted an expanded label approval ...

Amgen (AMGN) announced that the U.S. FDA has approved Uplizna as the first and only treatment for adults living with Immunoglobulin G4-related ...

The U.S. Food and Drug Administration has approved expanded use of Amgen's drug, Uplizna, to help reduce the risk of flares ...

Drugmaker stocks gained a temporary reprieve on Thursday as U.S. President Donald Trump spared pharmaceutical products from ...

Drugs from Novartis, Amgen and now Lilly have proven powerfully effective at reducing Lp(a). Whether that will translate to a ...

CHICAGO (Reuters) - The highest dose of an experimental drug developed by Eli Lilly significantly reduced levels of a ...